Tool Beta
Peptide Interaction Matrix A pharmacologically grounded reference for known and theoretical interactions between peptides. This matrix covers synergistic combinations, redundant mechanisms, and combinations that should be avoided. Not medical advice — always consult a clinician before combining compounds.
CJC-1295 + Ipamorelin
Synergistic / Safe GHRH analog + GHRP produce complementary GH release pathways. CJC-1295 stimulates somatotrophs via GHRH receptor; Ipamorelin activates ghrelin receptor (GHSR). Combined effect exceeds sum of individual effects.
CJC-1295 + GHRP-2
Synergistic / Safe Same complementary pathway as Ipamorelin, but GHRP-2 is less selective — also elevates cortisol and prolactin.
Semaglutide + Tirzepatide
High Risk / Avoid Both are GLP-1 receptor agonists. Combined use causes additive GLP-1 receptor stimulation, leading to excessive appetite suppression, nausea, and hypoglycemia risk.
Semaglutide + BPC-157
Low Risk No direct pharmacodynamic interaction. BPC-157's gastroprotective effects may theoretically mitigate GLP-1-induced GI discomfort.
BPC-157 + TB-500
Synergistic / Safe BPC-157 promotes angiogenesis and collagen synthesis via NO/cGMP pathway. TB-500 (Thymosin Beta-4) regulates actin polymerization and cell migration. Mechanisms are complementary for tissue repair.
Both promote wound healing through different pathways. BPC-157 via growth factor modulation; GHK-Cu via copper-dependent collagen synthesis and angiogenesis.
Semax + Selank
Synergistic / Safe Semax is a synthetic ACTH fragment with nootropic and neuroprotective effects. Selank is a synthetic tuftsin analog with anxiolytic properties. Both cross the blood-brain barrier and modulate neurotransmitter systems.
Semaglutide + CJC-1295
Moderate Risk GLP-1 agonists slow gastric emptying and may affect nutrient absorption. GH peptides increase metabolic rate and may alter glucose homeostasis. Both affect metabolic pathways.
Tesamorelin + Ipamorelin
Moderate Risk Both stimulate GH release — Tesamorelin via GHRH receptor, Ipamorelin via ghrelin receptor. Combined use produces supraphysiological GH elevation.
Bremelanotide + PT-141
High Risk / Avoid Bremelanotide IS PT-141. These are the same compound (different names). Taking both is effectively double-dosing.
BPC-157 + NSAIDs
Moderate Risk BPC-157 protects gastric mucosa from NSAID-induced damage in animal models. In humans, this may mask early signs of NSAID gastropathy.
Both have anti-inflammatory properties. GHK-Cu modulates gene expression; KPV (Lys-Pro-Val) is a melanocortin fragment with anti-inflammatory effects.
Retatrutide + Semaglutide
High Risk / Avoid Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. Semaglutide is a GLP-1 agonist. Combined use produces excessive incretin pathway activation.
Epithalon + Thymalin
Low Risk Epithalon is a synthetic pineal peptide (Ala-Glu-Asp-Gly) that may affect telomerase. Thymalin is a thymus peptide immunomodulator. Different target tissues.
MOTS-c is a mitochondrial-derived peptide that improves insulin sensitivity. CJC-1295 increases GH/IGF-1 which can reduce insulin sensitivity. Potentially opposing metabolic effects.